|Bid||1.75 x 1000|
|Ask||1.77 x 1000|
|Day's Range||1.72 - 1.81|
|52 Week Range||1.60 - 3.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov’s Chairman of the Board and Chief Medical Officer, Dr. Paul Waymack, of a motion to quash a subpoena for documents and testimony served on Dr. Waymack by the Securities and Exchange Commission (“SEC”), the SEC has commenced an action to enforce the subpoena. As stated by the SEC, “The application does not reflect a determination by the SEC or its staff that Waymack or Kitov Pharmaceuticals has violated any provisions of the federal securities laws or any provisions at issue in the Israel Securities Authority's investigation”.
Tel Aviv, Israel, Aug. 29, 2018-- Kitov Pharma Ltd., an innovative biopharmaceutical company, today provided a corporate update and reported financial results for the six months ended June 30, 2018.. “The ...
TASE: KTOV.TA), an innovative biopharmaceutical company, today announced that it has entered into a Stipulation of Settlement with respect to the shareholder class action lawsuits pending against it in Cohen v. Kitov Pharmaceuticals Holdings, Ltd., et al., Civil Action No. 1:17-cv-00917-LGS (District Court for the Southern District of New York), and Ng, v. Kitov Pharmaceuticals Holdings, Ltd., et al., Case No. 17CIV00620 and Zulch v. Kitov Pharmaceuticals Holdings, Ltd., et al., Case No. 17CIV01173 (both in Superior Court for the State of California) (collectively, the “Actions”). As previously disclosed, these lawsuits were filed against the Company alleging violations of U.S. federal securities laws. Under the terms of the proposed settlement, the classes in all of the Actions will receive aggregate consideration of $2.0 million.
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
TASE: KTOV), an innovative biopharmaceutical company, today announced that it will host a business update conference call on Monday July 2nd at 8:30 am Eastern Time. Management will discuss Kitov’s recent activities and accomplishments and provide information about ConsensiÔ , including efforts to finalize US commercialization partnerships, recent positive pre-clinical data for NT219, and financial information. NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development company.
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was FDA news that sent shares of Kitov Pharma blasting off on Thursday. Shares of Clearside Biomedical sunk despite positive topline results being announced ...
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KTOV as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a definitive license and commercialization deal with China-based Hebei Changshan Biochemical Pharmaceutical Co., Ltd ("Changshan"), granting the latter exclusive rights to import, manufacture, and distribute the Company's lead drug candidate, Consensi™, in China.
TEL AVIV, Israel, April 13, 2018 /PRNewswire/ -- Kitov Pharma (NASDAQ and TASE: KTOV), today announced that TyrNovo Ltd., a company majority-owned by Kitov, will present pre-clinical data on TyrNovo's anti-tumor resistance drug candidate, NT219, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, to be held on April 14-18, at the McCormick Place, Chicago, Illinois.
TEL AVIV, Israel, March 8, 2018 /PRNewswire/ -- Kitov Pharmaceuticals (KTOV) (KTOV), an innovative biopharmaceutical company, announced today that Dr. Gil Ben-Menachem, VP Business Development of TyrNovo, a Kitov Pharmaceuticals company, will present recent results from pre-clinical studies with NT219, a novel dual inhibitor of STAT3 and IRS1/2, at the 2018 BIO-Europe Spring® Conference at the RAI Convention Center, in Amsterdam, The Netherlands. NT219 is an innovative, unique small molecule targeting IRS1/2 and STAT, two signal proteins that are part of an anti-cancer drug resistance mechanism.
TASE: KTOV), an innovative biopharmaceutical company, announced today that it filed its Annual Report for 2017 on Form 20-F, including its full financial results for the year ended December 31, 2017. Consensi™, a combination drug that simultaneously treats pain caused by osteoarthritis and treats hypertension, is comprised of two FDA approved drugs, celecoxib (Celebrex®), an NSAID, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a drug designed to treat hypertension.
"The receipt of the FDA's permission to use Consensi as the brand name for our lead drug is another important step in executing on our corporate strategy and will facilitate the commercialization of KIT-302, once approved by the FDA, " stated J. Paul Waymack, M.D., Sc.D., Kitov's Chairman of the Board and Chief Medical Officer. Consensi™ is a combination drug that is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi™ is comprised of two FDA approved drugs, celecoxib (Celebrex®), a COX-2 inhibitor, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.
TASE: KTOV), an innovative biopharmaceutical company, announced today that it has received the U.S. Food and Drug Administration's (FDA) response to the NT219's pre-IND meeting package. FDA has agreed to the proposed Chemistry Manufacturing and Controls (CMC), preclinical, and clinical development plans for NT219. For the clinical development plan, the FDA agreed with TyrNovo's proposed development plan to test NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer.
TASE: KTOV), an innovative biopharmaceutical company, announced today that its randomized double-blind, placebo-controlled renal function clinical trial for its lead drug candidate, KIT-302, successfully met its primary efficacy endpoint. Data from the trial demonstrated that KIT-302 lowered systolic blood pressure a comparable amount to the widely used antihypertension drug, amlodipine besylate, thus meeting the trial's primary efficacy endpoint of achieving at least 50% of the amlodipine reduction (p=0.019).
- Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. - NT219 is a first-in-class drug candidate presenting a new paradigm of cancer treatment - overcoming tumors' cancer drug resistance. TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the acquisition of an additional 27% stake in TyrNovo Ltd., a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders. As announced on January 13, 2017, Kitov had acquired a controlling interest, which is now approximately 65% of TyrNovo. After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Kitov Pharmaceuticals Holdings Ltd (NASDAQ: KTOV ), following which we ...
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) filed the Company's New Drug Application (NDA) for KIT-302, its lead drug candidate, thereby accepting the NDA for a full review. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously.